Hypercalcemia

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, according to a press release from Celltrion.

The FDA has approved two new biosimilars of denosumab to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced.

The majority of adults with hypoparathyroidism achieved normal serum calcium levels with palopegteriparatide at 1 year without supplemental vitamin D or calcium, according to data from a phase 3 open-label extension.

PHILADELPHIA — Although rare, hypercalcemia should be treated as a potential threat for patients with from severe tophaceous gout, according to a case study presented at the ASN Kidney Week.

A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or denosumab in addition to adequate hydration for adults with moderate hypercalcemia of malignancy.